Consistent with nivolumab and toripalimab in RM-NPC, our study observed a numerically higher but not statistically significant ORR of PD-L1 positive patients than PD-L1 negative patients between TPS and CPS, as well as for KDR positive than KDR negative patients both in cohort 1 and cohort 2 patents. This evidence concerns the gene KDR and nasopharyngeal carcinoma.